CCR2 and neoplasm: CCR2 inhibitors (e.g., PF‐0413630950 and CCX87251), have demonstrated efficacy in reducing tumour‐associated macrophage infiltration in cancer models and may offer similar benefits in limiting lung inflammation in this context.